MacroGenics, Inc.
Aug 2, 2017

MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results

ROCKVILLE, Md., Aug. 02, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today provided a corporate progress update and reported financial results for the quarter ended June 30, 2017.

"MacroGenics' broad portfolio of product candidates continues to advance. We are very encouraged by the data we've seen to date in our Phase 1 study of flotetuzumab, a CD123 x CD3 bispecific DART® molecule, and we look forward to presenting the updated interim results from this trial in an oral presentation at ESMO in September," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.  "In addition, we continue to make progress with margetuximab, our B7-H3-based franchise and our PD-1-targeted franchise.  During the second quarter, our IND for MGD013, which targets PD-1 and LAG-3, was cleared by FDA and we expect to dose the first patients in the coming weeks. I look forward to sharing updates on our pipeline and further defining our future development strategies over the remainder of the year."

Key Pipeline Highlights

Margetuximab. Recent highlights related to the Company's Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2, include:

B7-H3 Franchise. MacroGenics is developing a portfolio of therapeutics that target B7-H3, a member of the B7 family of molecules involved in immune regulation. The Company is advancing multiple programs that target B7-H3 through complementary mechanisms of action that take advantage of this antigen's broad expression across multiple solid tumor types. These molecules include:

PD-1-Directed Immuno-Oncology Franchise. MacroGenics is advancing several PD-1-directed programs, which will enable both a broad set of combination opportunities across the Company's portfolio and provide further differentiation from existing PD-1-based treatment options. The first of these are:

Additional DART Clinical Programs. Other DART molecules being led by MacroGenics in Phase 1 clinical development include flotetuzumab (CD123 x CD3, also known as MGD006 and S80880), MGD007 (gpA33 x CD3) and MGD010 (CD32B x CD79B). Updates on these programs include:

Second Quarter 2017 Financial Results

Conference Call Information

MacroGenics will host a conference call today at 4:30 pm (EDT) to discuss financial results for the quarter ended June 30, 2017 and provide a corporate update. To participate in the conference call, please dial (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and provide the Conference ID: 50966747.

The recorded, listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.

(Amounts in thousands)
 June 30, 2017 December 31, 2016
Cash, cash equivalents and investments$243,660 $284,982
Total assets 274,846  311,263
Deferred revenue 12,440  14,306
Total stockholders' equity 231,348  268,751

(Amounts in thousands, except share and per share data)
 Three Months Ended June 30, Six Months Ended June 30,
  2017   2016  2017   2016
Revenue from collaborative agreements$1,081  $78,497 $2,359  $80,390
Revenue from government agreements 585   2,176  1,361   3,129
Total revenues 1,666   80,673  3,720   83,519
Costs and expenses:       
Research and development 34,461   33,340  67,262   60,686
General and administrative 8,384   7,239  15,846   13,372
Total costs and expenses 42,845   40,579  83,108   74,058
Income (loss) from operations (41,179)  40,094  (79,388)  9,461
Other income 525   370  1,078   640
Net income (loss) (40,654)  40,464  (78,310)  10,101
Other comprehensive income (loss):       
Unrealized gain (loss) on investments 25   7  (1)  64
Comprehensive income (loss)$(40,629) $40,471 $(78,311) $10,165
Basic net income (loss) per common share($1.14) $1.17 ($2.21) $0.29
Diluted net income (loss) per common share($1.14) $1.12 ($2.21) $0.28
Basic weighted average number of common shares outstanding 35,784,804   34,616,197  35,373,799   34,560,021
Diluted weighted average number of common shares outstanding 35,784,804   36,017,411  35,373,799   35,966,987

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at MacroGenics, the MacroGenics logo, DART and TRIDENT are trademarks or registered trademarks of MacroGenics, Inc.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. 

Jim Karrels, Senior Vice President, CFO
MacroGenics, Inc.

Karen Sharma, Senior Vice President
MacDougall Biomedical Communications